Demographic and clinical characteristics of patients with SLE and healthy individuals included in the study
| Patients with SLE (n=299) | Patients with SLE with APS (n=67) | Patients with SLE without APS (n=232) | Healthy individuals (n=72) | |
| Gender | ||||
| Female | 261 (87.2%) | 56 (83.6%) | 205 (88.4%) | 67 (93.1%) |
| Male | 38 (13.8%) | 11 (16.4%) | 27 (11.6%) | 5 (6.9%) |
| Race | ||||
| Caucasian | 297 (99.3%) | 67 (100%) | 230 (99.1%) | 72 (100%) |
| Other | 2 (0.7%) | 0 (2.4%) | 2 (0.9%) | 0 (0%) |
| Age (years) | ||||
| Mean±SD | 47±13.2 | 49.2±13.1 | 46.4±13.3 | 43.4±12 |
| Disease manifestations | ||||
| Venous thrombosis | 57 (18.7%) | 45 (68.2%) | 12 (5.2%) | |
| Pulmonary embolism | 8 (2.7%) | 7 (10.4%) | 1 (0.4%) | |
| Arterial thrombosis | 58 (19.4%) | 22 (32.8%) | 36 (15.5%) | |
| Pregnancy complications | – | 10 (14.9%) | – | |
| Antibodies | ||||
| aPL negative | 191 (63.9%%) | 0 (0%) | 191 (82%) | |
| aPL positive | 108 (36.1%) | 67 (100%) | 41 (17.6%) | |
| High aPL profile | 62 (57.4%) | 51 (76.1%) | 11 (26.8%) | |
| Low aPL profile | 46 (42.6%) | 16 (23.9%) | 30 (73.2%) | |
| Anti-CL | 90 (30.1%) | 55 (82.1%) | 35 (15%) | |
| Anti-β2GPI | 56 (18.2%) | 39 (58.2%) | 17 (7.3%) | |
| LA | 39 (13%) | 35 (52.2%) | 4 (1.7%) | |
anti-β2GPI, anti-beta2 glycoprotein I; aPL, antiphospholipid antibodies; APS, antiphospholipid syndrome; CL, cardiolipin; LA, lupus anticoagulant; SLE, systemic lupus erythematosus.